NEKTAR THERAPEUTICS Form 8-K November 02, 2011

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 2, 2011

## NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter)

Delaware 0-24006 94-3134940 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.)

455 Mission Bay Boulevard South San Francisco, California 94158 (Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: (415) 482-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On November 2, 2011, Nektar Therapeutics, a Delaware corporation ("Nektar"), issued a press release (the "Press Release") announcing its financial results for the quarter ended September 30, 2011. A copy of the Press Release is furnished herewith as Exhibit 99.1.

On October 26, 2011, Nektar announced that it would hold a Webcast conference call on November 2, 2011 to review its financial results for the quarter ended September 30, 2011. This conference call is accessible through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com.

On this conference call, management expects to provide information regarding Nektar's business and to make forward-looking statements, including statements regarding pre-clinical and clinical development plans, the medical and commercial potential for certain of Nektar's drug candidates, the value and potential of Nektar's technology, the projected Phase 3 clinical trial start date for NKTR-102 in metastatic breast cancer and Amikacin Inhale (partnered with Bayer), the future regulatory and development strategy for NKTR-102 in platinum resistant/refractory ovarian cancer, the timing and availability of clinical results, the timing of future events related to the advancement of our drug candidate pipeline including potential future regulatory filings and submissions with health authorities, financial guidance for 2011, and certain other future events. This information and these forward-looking statements involve substantial risks and uncertainties including but not limited to:

- Nektar's proprietary drug candidates, including NKTR-118, NKTR-102, NKTR-181 and Amikacin Inhale are in clinical development and the risk of failure remains high and can unexpectedly occur at any time due to lack of efficacy, frequency and severity of adverse safety events, manufacturing challenges, regulatory delays, changes in regulatory requirements (e.g., additional or expanded clinical studies), or other factors that can negatively impact drug development.
- The preliminary Phase 2 results for NKTR-102 in ovarian and breast cancer previously announced or presented by Nektar remain subject to final data gathering and audit confirmation procedures. Therefore, the final results for the ovarian and breast cancer trials may differ materially and adversely from previously reported data after these audit and verification procedures are completed.
- The expanded Phase 2 study in women with platinum-resistant/refractory ovarian cancer could change the efficacy results (e.g. overall response rates, progression-free survival, overall survival etc.) and safety observations (e.g., frequency and severity of serious adverse events). As such, the overall results from the Phase 2 study for platinum-resistant/refractory ovarian cancer remain subject to change and the final results could be materially and adversely different from results previously announced.
- •Acceptance and approval of a new drug application (NDA) by the United States Food and Drug Administration (FDA) almost always requires the sponsor to conduct comparative Phase 3 clinical studies prior to acceptance, review and/or approval of an NDA. As a result, acceptance for review and/or approval of an NDA submitted to the FDA based on overall response rate from our single-arm Phase 2 study in platinum-resistant/refractory ovarian cancer would be unusual and is highly unlikely—therefore we are not expecting the FDA to accept and/or approve an accelerated NDA based on our Phase 2 clinical study in platinum resistant/refractory ovarian cancer. The FDA has significant discretion to determine what constitutes a high unmet medical need, what therapies should be considered available to patients regardless of which therapies are approved or typically used in a particular setting, the relevance of certain efficacy end points (e.g. overall response rate, progression free survival, overall survival), and the number of patients required to be studied to demonstrate sufficient therapeutic benefit and safety profile. One or more of such judgments and determinations by the FDA could impair Nektar's ability to submit an accelerated NDA for platinum resistant/refractory ovarian cancer patients, and even if submitted, whether the FDA would accept it for

review and/or approve the NDA.

- •The timing and/or success of the commencement or end of clinical trials, including without limitation the anticipated Phase 3 commencement for NKTR-102 in metastatic breast cancer by the end of 2011 and Amikacin Inhale by mid-2012, may be delayed or unsuccessful due to regulatory delays, clinical trial design and the need to obtain regulatory concurrence for such designs, manufacturing challenges, required clinical trial administrative actions (i.e. clinical research organization contracting matters, institutional review board approvals at study sites etc.), slower than anticipated patient enrollment, changing standards of care, clinical outcomes, or financial constraints. For example, Nektar has experienced several significant delays in finalizing the commercial device design for Amikacin Inhale and successful completion of this device design and the commercial scale-up effort is an essential element to enabling the future start of the planned Phase 3 trial—these activities are ongoing and remain subject to a substantial risk of failure until such activities are successfully completed.
- •The discussion of NKTR-181 by management on the conference call is based on preclinical and data from the first Phase 1 clinical study and there is a risk that future clinical results may not confirm one or more of these results and observations. In addition, although Nektar has conducted various experiments using laboratory and home-based chemistry techniques that so far have been unable to convert NKTR-181 into a rapidly-acting, more abusable opioid, in the future, an alternative chemistry technique, process or method of administration may be discovered to enable the conversion of NKTR-181 into a more abusable opioid which would significantly and negatively impact the potential of NKTR-181.

- Scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platforms to potential new drug candidates is therefore very uncertain and unpredictable and one or more research and development programs could fail.
- Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future.
- The outcome of any intellectual property or other litigation related to Nektar's proprietary drug candidates (or partnered drug candidates where Nektar has indemnification responsibility) is unpredictable and could have a material adverse effect on Nektar's business, results of operations and financial condition.
- The market sizes for Nektar's proprietary and partnered product programs are based on management's current estimates (and in some cases estimates communicated to us by our collaboration partners or published by financial analysis) only and actual market sizes may differ materially and adversely.
- Management's financial projections for Nektar's 2011 annual revenue, certain annual expense category estimates, and year-end cash position are subject to the significant risk of unplanned revenue short-falls, unplanned expenses, and expenses being higher than planned, any of which could significantly and adversely affect Nektar's actual 2011 annual financial results and end of year cash position.
- •Other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q filed with the SEC on August 4, 2011.

Actual results could differ materially from the forward-looking statements and Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Press release titled "Nektar Therapeutics Reports Third Quarter 2011 Financial Results" issued by Nektar Therapeutics on November 2, 2011.

#### **SIGNATURES**

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

By: /s/ Gil M. Labrucherie

Gil M. Labrucherie General Counsel and Secretary

Date: November 2, 2011

#### EXHIBIT INDEX

Exhibit No. 99.1	Description  Press release titled "Nektar Therapeutics Reports Third Quarter 2011
	Financial Results" issued by Nektar Therapeutics on November 2, 2011.
e="margin-top:0px" width=45.333>	
Common stock issued at merger	256,000
	2,000,000
	2,000
	(2,000)
	-
	-

Common stock issued for future services in August 2004 at \$0.12/share 637,500 638 74,362 75,000 Conversion of note payable in December 2004 at \$0.16/share

187,500

	187
	29,813
	-
	-
	-
	-
	-
Net loss for the year ended December 31, 2004	30,000
	-
	-
	-
	-

-

(722,146)

(722,146)

#### BALANCE AT DECEMBER 31, 2004

18,425,000

18,425

342,576

\_

-

-

(15,827)

(722,146)

(376,972)

Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K	
Common stock issued in private placement in April 2005 at \$0.25/share	
	4,000,000
	4,000
	996,000
	-
	-

-

1,000,000

Conversion of notes payable in May 2005 at \$0.16/share

3,118,750

3,119

495,881

\_

\_

\_

\_

\_

499,000

Subscription receivable	
	-
	-
	-
	(6,500)
	, ,
	_
	_
	-
	-
	(6,500)
Common stock issued for future services in August 2005, valued at \$2.79/share	
	210,000
	210
	585,290

	-
	-
	-
	-
	-
	585,500
Common stock issued for future services in August 2005, valued at \$2.92/share	
	200,000
	200
	583,800
	-
	-

-

584,000

Warrants issued for services in May 2005, vested during 2005, valued at \$1.13/share

\_

37,000

-

-

-

-

-

37,000

Warrants issued for services in September 2005, vested during 2005, valued at \$1.45/share


24,200 24,200

Warrants issued for services in October 2005, vested during 2005, valued at \$0.53/share

15,900

-

	-
	-
	-
	-
	15,900
Warrants issued for future services in December 2005, vested during 2005,	
warrants issued for future services in December 2005, vested during 2005,	valued at \$1.13/3hare
	435,060
	-
	-
	-



265,455 265,455 Exercise of warrants in December 2005 at \$0.25/share 300,000 300 74,700

75,000 Net loss for the year ended December 31, 2005

(1,721,765)



BALANCE AT DECEMBER 31, 2005


26,253,750

26,254

#### Е

Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K	
	3,590,407
	(6,500)
	(318,545)
	-
	(15,827)
	(2,443,911)

831,878




850

850,000

425,000

Common stock issued for future services in February 2006, valued at \$0.90/share



Common stock issued for future services in June 2006, valued at \$1.45/share

-


620,000

25,000

25

36,225

25



66,500 Warrants issued for future services in June 2006, vested during 2006, valued at \$1.55/share 465,996

Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K	
	-
	_
	-
	-
Options issued for services in February 2006, vested during 2006, valued at \$1.01/share	
	_
	_
	428,888
	_
	-
	-
	_
	-
	-
Contributed capital related to accrued interest	

35,624

35,624

Subscription receivable

6,500 6,500 Amortization of deferred charges 318,545

	-
	318,545
Unrealized gain (loss) on securities	
	-
	-
	_
	-
	-
	(26,000)
	_
	-
Net loss for the year ending December 31, 2006	(26,000)
2.00 loss for the year entiting December 51, 2000	

32

(2,933,809)

(2,933,809)

#### BALANCE AT DECEMBER 31, 2006

27,888,750

\$

27,889

\$

5,966,430

\$

\_

\$

\$

(26,000)

\$

(15,827)

\$

(5,377,720)

\$

574,772

The accompanying notes are an integral part of these financial statements.

F-4

## Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K LIGHTWAVE LOGIC, INC.

(A Development Stage Company)

#### STATEMENT OF STOCKHOLDERS EQUITY

FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE) TO DECEMBER 31, 2012 (CONTINUED)

Subscription

	Number of Shares	Common Stock	Paid-in Capital	Receivable/ Receivable for Issuance of Common Stock	Deferred Charges	Unrealized Loss on Securities	Accumulated Deficit	Deficit Accumulated During Development Stage	Total
BALANCE AT DECEMBER 1, 2006	27,888,750 \$	3 27,889 \$	5,966,430 \$		<b>;-</b> :	\$ (26,000)	\$ (15,827)\$	C	574,772
Common stock ssued in rivate lacement luring 2007 at 0.50/share Common stock	2,482,000	2,482	1,238,518	-	-	-	-	-	1,241,000
ssued in rivate lacement luring 2007 at	1,767,540	1,768	1,058,756	-	-	-	-	-	1,060,524
0.60/share Common stock ubscription escinded luring 2007 at 0.50/share Common stock	(400,000)	(400)	(199,600)	-	-	-	-	-	(200,000
ssued for uture services n February 1007, valued at	151,785	152	106,098	-	-	-	-	-	106,250

0.70/share

			_						,
Common stock ssued for uture services	1 000 000	1 000	570,000						500,000
n March 2007, ralued at 0.58/share Common stock ssued for	1,000,000	1,000	579,000	-	-	-	-	-	580,000
ervices and ettlement for ccounts ayable in April 007, valued at 0.35/share Common stock ssued for	100,000	100							
ervices in Dctober 2007, ralued at 0.68/share Common stock ssued for	150,000	150	101,850	-	-	-	-	-	102,000
ervices in October 2007, alued at 0.90/share Common stock ssued for	150,000	150	134,850	-	-	-	-	-	135,000
ervices in November 2007, valued at 0.72/share Warrants ssued for ervices in	400,000	400	287,600	-	-	-	-	-	288,000
September 005, vested Juring 2007, alued at 11.45/share Warrants ssued for	-	-	36,370	-	-	-	-	-	36,370
ervices in Aarch 2007, ested during 2007, valued at 0.63/share	-	-	52,180	-	-	-	-	-	52,180
Varrants ssued for ervices in	-	-	293,476	-	-	-	-	-	293,476

April 2007,

			zugar Filling. IN	ILNIAN INC	.INAFEUTI	JO - FUIII O-	IX		
ested during 007, valued at 0.69/share Varrants ssued for									
ervices in April 2007, ested during 007, valued at 0.63/share Varrants ssued for	-	-	140,490	-	-	-	-	-	140,490
ervices in May 1007, vested luring 2007, ralued at 10.56/share Warrants ssued for ervices in	-	-	52,946	-	-	-	-	-	52,946
October 2007, ested during 2007, valued at 0.61/share Varrants ssued for ervices in	-	-	61,449	-	-	-	-	-	61,449
October 2007, ested during 2007, valued at 0.78/share Varrants ssued for ervices in	-	-	52,292	-	-	-	-	-	52,292
December 1007, vested luring 2007, ralued at 10.55/share Dptions issued or services in	-	-	1,159	-	-	-	-	-	1,159
February 2006, ested during 1007, valued at 1.01/share 1.0 or services in	-	-	17,589	-	-	-	-	-	17,589
ebruary 2006, ested during 1007, valued at	-	-	43,757	-	-	-	-	-	43,757

1.09/share

			0						
Options issued or services in November 1007, vested luring 2007, alued at 10.60/share	-	-	41,653	-	-	-	-	-	41,653
Varrants ssued for uture services n April 2007, ested during 007, valued at 0.70/share Deferred	-	-	348,000	-	-	-	-	-	348,000
harges for ommon stock ssued for uture services n March 2007, valued at 0.58/share	-	-	-	-	(928,000)	-	-	-	(928,000
Amortization of deferred harges	-	-	-	-	773,333	-	-	-	773,333
Jnrealized gain loss) on ecurities Vet loss for the	-	-	-	-	-	(32,610)	-	-	(32,610
ear ending December 31,	-	-	-	-	-	-	-	(4,223,449)	(4,223,449
BALANCE AT DECEMBER 1, 2007	33,690,075	33,690	10,449,763	-	(154,667)\$	(58,610)	(15,827)	(9,601,169)	653,180
Common stock ssued in rivate lacement luring 2008 at 0.60/share Common stock	690,001	690	413,310	-	-	-	-	-	414,000
ssued for ervices in Aarch 2008, alued at	100,000	100	74,900	-	-	-	-	-	75,000
0.75/share	200,000	200	250,000						260,000

Common stock

ssued for

200,000

200

359,800

360,000

i			0						
ervices in August 2008, alued at 1.80/share Exercise of									
varrants at 0.25/share Exercise of varrants at 0.25/share,	320,000	320	79,680	-	-	-	-	-	80,000
ursuant to November 1008 adjusted tock offering Exercise of	641,080	641	159,629						160,270
varrants at 0.50/share Varrants ssued for ervices in	270,000	270	134,730	-	-	-	-	-	135,000
September 2005, vested luring 2008, alued at 11.45/share Varrants ssued for	-	-	27,014	-	-	-	-	-	27,014
ervices in March 2007, ested during 2008, valued at 30.63/share Warrants ssued for	-	-	10,885	-	-	-	-	-	10,885
ervices in April 2007, rested during t008, valued at t0.69/share Varrants ssued for	-	-	121,713	-	-	-	-	-	121,713
ervices in April 2007, ested during 2008, valued at 10.63/share	-	-	48,738	-	-	-	-	-	48,738
Varrants ssued for ervices in May 2007, vested	-	-	31,444	-	-	-	-	-	31,444

luring 2008,

ĺ									
ralued at									
0.56/share									Ī
Varrants									Ī
ssued for									
ervices in									
December	_	_	12,487	_	_	-	_	_	12,487
007, vested			12,407						12, 10,
luring 2008,									
alued at									Ī
0.55/share									Ī
Options issued									Ī
or services in									Ī
Vovember									Ī
007, vested	-	-	286,803	-	-	-	-	-	286,803
luring 2008,									Ī
alued at									
0.60/share									Ī
Options issued									Ī
or services in									Ī
anuary 2008,									
ested during	-	-	30,750	-	-	-	-	-	30,750
008, valued at									Ī
0.60/share									Ī
Options issued									Ī
or services in									Ī
									Ī
uly 2008,	-	-	114,519	-	-	-	-	-	114,519
rested during									Į
008, valued at									Į.
1.48/share									Į
Options issued									Į
or services in									Į
August 2008,	_	-	525,263	-	_	_	-	_	525,263
ested during			320,200						<i>52</i> 5,
008, valued at									Į
1.36/share									Į
Options issued									Į.
or services in									Ī
lovember									Į
008, vested	-	-	6,439	-	-	-	-	-	6,439
luring 2008,			•						· .
alued at									Į
0.50/share									Į.
Varrants									Ī
ssued for									Ī
uture services									Į.
									Ī
n March 2008,	-	-	332,000	- (33)	32,000)	-	-	-	
ested through			•	-	, ,				Ī
eptember									
008, valued at									Ī
0.83/share									
	-	-	976,193	-	-	-	-	-	976,193
i									

Varrants

ssued for									
ervices in May									
008, vested									
hrough									
eptember									
008, valued at									
1.63/share									
Amortization									
f deferred	-	-	-	-	431,337	-	-	-	431,337
harges									
Receivable for									
he issuance of	-	-	-	(12,500)	-	-	-	-	(12,500
ommon stock									
Realized loss						59 610			59 610
eclassification	-	-	-	-	-	58,610	-	-	58,610
let loss for the									
ear ending								(4 240 607)	(4 240 607
December 31,	-	-	-	-	-	-	-	(4,340,607)	(4,340,007
008									
BALANCE AT									
DECEMBER 1, 2008		35,911 \$14,19	96,060 \$	(12,500)\$	5 (55,330)\$	- \$	(15,827)\$	(13,941,776)\$	206,538
1									

The accompanying notes are an integral part of these financial statements.

# Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K LIGHTWAVE LOGIC, INC.

(A Development Stage Company)

## STATEMENT OF STOCKHOLDERS EQUITY

# FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE) TO DECEMBER 31, 2012 (CONTINUED)

DALANCE	Number of Shares	Common Stock	Paid-in Capital	Subscription Receivable/ Receivable for Issuance of Common Stock	Deferred Charges	Unrealized Loss on Securities	Accumulated Deficit	Deficit Accumulated During Development Stage	Total
BALANCE AT DECEMBER		\$ 25.011	\$	\$ (12,500)	\$	\$	\$ (15.827)	\$ \$	206.529
31, 2008	35,911,156	35,911	14,196,060	(12,500)	(55,330)	-	(15,827)	(13,941,776)	206,538
Rights to purchase shares issued in January 2009, vested during 2009, valued at \$0.33/share Common stock issued for services in January 2009, valued at \$0.58/share Common stock issued for services for	100,000	100	132,058 57,900		-	-	-	-	132,058 58,000
for services & settlement for accounts payable January 2009 valued at \$0.25/share	100,000	100	24,900	-	-	-	-	-	25,000

Exercise of purchase right agreement in January 2009 at \$0.25/share Exercise of warrants at \$0.25/share, pursuant to November 2008 adjusted	180,550	181	44,957	-	_	-	-	-	45,138
stock offering Exercise of warrants at	1,279,336	1,279	318,555			-			319,834
\$0.001/share Exercise of warrants at	400,000	400	-	-		-	-	-	400
\$1.00/share Options issued for services in November 2007, vested during 2009,	355,000	355	354,645			-			355,000
valued at \$0.60/share Options issued for services in January 2008, vested during 2009, valued	-	-	199,234	-	-	-	-	-	199,234
at \$0.60/share Options issued for services in July 2008, vested during 2009, valued	-	-	13,583	-		-	-	-	13,583
at \$1.48/share Options issued for services in August 2008, vested during 2009, valued	-	-	67,838	-	-	-	-	-	67,838
at \$1.36/share Options issued for services in November	-	-	623,246 61,346	-	- -	-	-	-	623,246 61,346

2008, vested during 2009, valued at \$0.50/share Options issued for services in January 2009,									
vested during 2009, valued at \$0.53/share Options issued for services in February 2009, vested	-	-	13,136	-	-	-	-	-	13,136
during 2009, valued at \$0.38/share Options issued for services in June 2009,	-	-	9,583	-	-	-	-	-	9,583
vested during 2009, valued at \$0.85/share Warrants issued for services in June 2009, vested during	-	-	21,085	-	-	-	-	-	21,085
2009, valued at \$0.85/share Contribution of accrued payroll in	-	-	177,881	-	-	-	-	-	177,881
February 2009 Amortization	-	-	52,129	-	-	-	-	-	52,129
of deferred charges Payment for the issuance	-	-	-	-	55,330	-	-	-	55,330
of common stock Common stock issued for services in June 2009,	-	-	-	12,500	-	-	-	-	12,500
valued at \$0.34/share	116,000	116	39,884	-	-	-	-	-	40,000

			5 5						
Common stock issued for services & settlement for accounts									
payable June 2009 valued at \$0.34/share Common stock issued in private placement	145,000	145	49,855	-	-	-	-	-	50,000
during June 2009 at \$0.34/share Common stock issued for services in	2,479,500	2,480	852,520	-		-	-	-	855,000
July 2009, valued at \$0.75/share Net loss for the year ending	100,000	100	74,900	-	-	-	-	-	75,000
December 31, 2009	-	-	-	-	_	-	-	(2,721,871)	(2,721,871)
BALANCE AT December 31, 2009	41,166,542	41,167	17,385,295	-		- -	(15,827)	(16,663,647)	746,988
Options issued for services in November 2007, vested during 2010, valued at									
\$0.60/share Options issued for services in January 2008, vested during	-	-	174,866	-	-		-	-	174,866
2010, valued at \$0.60/share Options issued for services in July 2008, vested during	-	-	14,873 74,061	-	- -	-	-	-	14,873 74,061

2010, valued at \$1.48/share Options issued for services in August 2008, vested during 2010, valued at \$1.36/share	_	_	643,812	_	_	_	_	_	643,812
Options issued for services in November 2008, vested during 2010, valued at			013,012						015,012
\$0.50/share Warrants issued for services in June 2009, vested during 2010, valued	-	-	31,478	-	-	-	-	-	31,478
at \$0.85/share Warrants issued for services in January 2010, vested during 2010, valued	-	-	213,459	-	-	-	-	-	213,459
at \$1.83/share Warrants issued for services in March 2010, vested during 2010, valued			580,167			-			580,167
at \$1.86/share Options issued for services in August 2010, vested during 2010, valued	-	-	214,063	-	-	-	-	-	214,063
at \$1.31/share Options issued for services in December 2010, vested during 2010,	-	-	27,434 286,002	-	-	-	-	-	27,434 286,002

valued at \$1.14/share Exercise of								
warrants at \$0.25/share Exercise of	947,200	947	235,853	-	-	-	-	- 236,800
options at \$0.25/share Exercise of	15,000	15	3,735	-	-	-	-	- 3,750
warrants at \$0.345/share Exercise of	10,000	10	3,440	-	-	-	-	- 3,450
warrants at \$0.50/share Exercise of	25,000	25	12,475	-	-	-	-	- 12,500
warrants at \$1.00/share Common	282,500	283	282,218	-	-	-	-	- 282,500
stock issued in private placement during 2010 at \$1.00/share Common stock issued		1,500	1,498,500	-	-	-	-	- 1,500,000
for services in August 2010, valued at \$1.25/share Common stock issued	4,800	4	5,996	-	-	-	-	- 6,000
for services in November 2010, valued at \$0.93/share Common stock issued for services in	5,000	5	4,645	-	-	-	-	- 4,650
December 2010, valued at \$01.20/share Net loss for the year ending December 31, 2010	10,000	10	11,990	-	-	-	-	- 12,000 - (3,713,232)
BALANCE	43,966,042 \$	9	\$ \$	\$	\$	\$	\$	\$
AT DECEMBER		43,966	21,704,361	-	-	- (1	15,827) (20,3	76,879) 1,355,621

The accompanying notes are an integral part of these financial statements.

F-6

# Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K LIGHTWAVE LOGIC, INC.

(A Development Stage Company)

## STATEMENT OF STOCKHOLDERS EQUITY

# FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE) TO DECEMBER 31, 2012 (CONTINUED)

				Subscription Receivable/ Receivable				Deficit Accumulated	
	Number of	Common	Paid-in	for Issuance	Deferred	Unrealized Loss	Accumulated	During	
	Shares	Stock	Capital	of Common Stock	Charges	on Securities	Deficit	Development Stage	Total
BALANCE AT DECEMBER 31, 2010	43,966,042	\$ 43,966	\$ 21,704,361	\$ -	\$ -	\$ -	\$ (15,827)	\$ (20,376,879)	\$ 1,355,621
Common stock issued for services in March 2011, valued at \$1.45/share Options	10,000	10	14,490	-	-	-	-	-	14,500
issued for services in January 2008, vested during 2011, valued at \$0.60/share Options	-	-	285	-	-	-	-	-	285
issued for services in July 2008, vested during 2011, valued at \$1.48/share	-	-	39,829	-	-	-	-	-	39,829
Options issued for services in August 2008,	-	-	383,881	-	-	-	-	-	383,881

vested during 2011, valued at \$1.36/share Options issued for									
services in November 2008, vested during 2011, valued at \$0.50/share Warrants	-	-	26,648	-	-	-	-	-	26,648
issued for services in January 2010, vested during 2011, valued at \$1.83/share Warrants	-	-	306,765	-	-	-	-	-	306,765
issued for services in March 2010, vested during 2011, valued at \$1.86/share	-	-	64,983	-	-	-	-	-	64,983
Options issued for services in August 2010, vested during 2011, valued at \$1.31/share	-	-	65,447	-	-	-	-	-	65,447
Options issued for services in December 2010, vested during 2011, valued at \$1.14/share Warrants	-	-	212,136	-	-	-	-	-	212,136
issued for services in January 2011, vested during 2011, valued	-	-	36,585	-	-	-	-	-	36,585
at \$1.05/share Warrants issued for services in April 2011,	-	-	109,820	-	-	-	-	-	109,820

vested during 2011, valued at \$0.98/share Options issued for services in									
May 2011, vested during 2011, valued at \$0.97/share Options issued for	-	-	79,702	-	-	-	-	-	79,702
services in August 2011, vested during 2011, valued at \$0.82/share Options issued for	-	-	17,204	-	-	-	-	-	17,204
services in November 2011, vested during 2011, valued at \$0.53/share Options	-	-	4,384	-	-	-	-	-	4,384
issued for services in December 2011, vested during 2011, valued at \$0.82/share	-	-	53,124	-	-	-	-	-	53,124
Warrants issued for services in December 2011, vested during 2011, valued at \$1.05/share Common	-	-	1,288	-	-	-	-	-	1,288
for commitment shares, valued at \$1.08/share	150,830	151	162,746	-	-	-	-	-	162,896
Common stock issued to institutional	185,185	185	199,815	-	-	-	-	-	200,000

investor, valued at \$1.08/share Common stock issued									
for additional commitment shares, valued at \$1.15/share Common	3,017	3	3,467	-	-	-	-	-	3,470
stock issued for services in June 2011, valued at \$1.04/share Common	10,000	10	10,390	-	-	-	-	-	10,400
stock issued in private placement during 2011 at \$1.00/share Common	1,000,000	1,000	999,000	-	-	-	-	-	1,000,000
stock issued for services in September 2011, valued at \$1.45/share	10,000	10	14,490	-	-	-	-	-	14,500
Common stock issued for services in May 2011 through August 2011, valued at \$0.90/share to \$1.25/share	2,018	2	2,161	-	-	-	-	-	2,163
Net loss for the nine months ending December 31, 2011	-	-	-	-	-	-	-	(3,482,622)	(3,482,622)
BALANCE AT DECEMBER 31, 2011	45,337,092	\$ 45,337	\$ 24,513,000	\$ -	\$ -	\$ -	\$ (15,827)	\$ (23,859,501)	\$ 683,009

The accompanying notes are an integral part of these financial statements.

# Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K LIGHTWAVE LOGIC, INC.

(A Development Stage Company)

## STATEMENT OF STOCKHOLDERS EQUITY

# FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE) TO DECEMBER 31, 2012 (CONTINUED)

	Number of Shares	Common Stock	Paid-in Capital	Subscription Receivable/ Receivable for Issuance of Common Stock	Deferred	Unrealized Loss on Securities	Accumulated  Deficit	Deficit Accumulated During Development Stage	Total
BALANCE AT DECEMBER 31, 2011	45,337,092		\$ 24,513,000	\$	\$	\$	\$ (15,827)		683,009
Common stock issued to institutional investor, valued at \$1.013/share Common stock issued for additional commitment	197,433	198	199,802	-	-	-	_	-	200,000
shares, valued at \$1.64/share Common stock issued to institutional investor,	3,017	3	4,945	-	-	-	-	-	4,948
valued at \$1.197/share Common stock issued for additional commitment shares, valued	167,084	167	199,832	-	-	-	-	-	199,999
at \$1.67/share	3,017 316,455	3 317	5,035 499,682	-	-	-	- -	-	5,038 499,999

Common stock issued to institutional investor, valued at \$1.58/share Common stock issued for additional commitment									
shares, valued at \$2.87/share Common stock issued to institutional investor,	7,542	7	21,638	-	-	-	-	-	21,645
valued at \$1.66/share Common stock issued for additional commitment	120,482	120	199,880	-	-	-	-	-	200,000
shares, valued at \$1.97/share Common stock issued to institutional investor,	3,017	3	5,940	-	-	-	-	-	5,943
valued at \$1.897/share Common stock issued for additional commitment	158,144	158	299,841	-	-	-	-	-	299,999
shares, valued at \$2.60/share Common stock issued to institutional investor,	4,525	5	11,760	-	-	-	-	-	11,765
valued at \$2.073/share Common stock issued for additional commitment	96,479	97	199,904	-	-	-	-	-	200,001
shares, valued at \$2.64/share Common stock issued to institutional	3,017 91,324	3 92	7,962 199,908	-	- -	-	-	-	7,965 200,000

investor, valued at \$2.19/share Common stock issued for additional commitment shares, valued									
at \$2.23/share Common stock issued to institutional investor, valued at	3,017	3	6,725	-	-	-	-	-	6,728
\$1.68/share Common stock issued for additional commitment shares, valued	119,048	119	199,882	-	-	-	-	- 2	200,001
at \$1.80/share Common stock issued to institutional investor,	3,017	3	5,428	-	-	-	-	-	5,431
valued at \$1.81/share Common stock issued for additional commitment	220,994	221	399,778	-	-	-	-	- 3	399,999
shares, valued at \$1.88/share Common stock issued for additional commitment	3,017	3	5,669	-	-	-	-	-	5,672
shares, valued at \$1.92/share Common stock issued to institutional investor,	3,017	3	5,790	-	-	-	-	-	5,793
valued at \$1.53/share Common stock issued for additional commitment	130,719	131	199,870	-	-	-	-	- 2	200,001
shares, valued at \$1.60/share	3,017	3	4,824	-	-	-	-	-	4,827

Common stock issued to institutional investor, valued at									
\$1.667/share Common stock issued for additional commitment	119,976	120	199,880	-	-	-	-	-	200,000
shares, valued at \$1.93/share Common stock issued to institutional investor,	3,017	3	5,820	-	-	-	-	-	5,823
valued at \$1.51/share Common stock issued for additional commitment	132,450	132	199,867	-	-	-	-	-	199,999
shares, valued at \$1.70/share Common stock issued to institutional	6,034	6	10,252	-	-	-	-	-	10,258
investor, valued at \$1.677/share Common stock issued for additional	119,261	119	199,882	-	-	-	-	-	200,001
commitment shares, valued at \$1.35/share Common stock issued to institutional	3,017	3	4,070	-	-	-	-	-	4,073
investor, valued at \$1.13/share Common stock issued for additional	176,991	177	199,823	-	-	-	-	-	200,000
commitment shares, valued at \$1.28/share Common stock issued to institutional	3,017 177,510	3 178	3,859 199,823	-	- -	-	-	-	3,862 200,001

investor, valued at \$1.1267/share Common stock issued for additional commitment shares, valued									
at \$1.28/share Common stock issued to institutional investor, valued at	3,017	3	3,859	-	-	-	-	-	3,862
\$1.107/share Common stock issued for additional commitment	180,668	180	199,820	-	-	-	-	-	200,000
shares, valued at \$1.18/share Common stock issued to institutional investor,	3,017	3	3,557	-	-	-	-	-	3,560
valued at \$1.10/share Common stock issued for additional commitment	181,818	182	199,818	-	-	-	-	-	200,000
shares, valued at \$1.08/share Common stock issued to institutional investor,	3,017	3	3,255	-	-	-	-	-	3,258
valued at \$1.063/share Common stock issued for additional commitment	188,147	188	199,812	-	-	-	-	-	200,000
shares, valued at \$1.09/share Common stock issued to institutional investor,	3,017	3	3,286	-	-	-	-	-	3,289
valued at \$1.02/share	196,078	196	199,803	-	-	-	-	-	199,999

Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K

Common stock issued for additional commitment shares, valued at \$1.04/share Common stock issued to institutional	1,508	2	1,566	-	-	-	-	- 1,568
investor, valued at \$1.02/share Common stock issued for additional	98,039	98	99,902	-	-	-	-	- 100,000
commitment shares, valued at \$1.10/share Common stock issued to institutional	2,262	2	2,486	-	-	-	-	- 2,488
investor, valued at \$1.00/share Common stock issued for additional	350,000	350	349,650	-	-	-	-	- 350,000
commitment shares, valued at \$1.00/share	3,017	3	3,014 \$	-	-	-	-	- 3,017 \$
Subtotal	48,949,352	48,950 29	9,490,199	-	-	-	(15,827) (23,85	59,501) 5,663,821

The accompanying notes are an integral part of these financial statements.

# Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K LIGHTWAVE LOGIC, INC.

(A Development Stage Company)

## STATEMENT OF STOCKHOLDERS EQUITY

# FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE) TO $\label{eq:decomposition} \text{DECEMBER 31, 2012 (CONTINUED)}$

	Number of Shares	Common Stock	Paid-in Capital	Subscription Receivable/ Receivable for Issuance of Common Stock	Deferred	Unrealized Loss on Securities	Accumulated Deficit	Deficit Accumulated During Development Stage	Total
		\$	\$	\$	\$	\$	\$	\$	\$
Subtotal	48,949,352	48,950	29,490,199	-	-	-	(15,827)	(23,859,501)	5,663,821
Exercise of options at \$0.65/share Exercise of	250,000	250	162,250	-	-	-	-	-	162,500
warrants at \$1.25/share	40,000	40	49,960	-	-	-	-	-	50,000
Exercise of warrants at \$0.34/share Exercise of warrants at \$0.25/share	20,000	20 900	6,880 224,100	-	-	-	-	-	6,900 225,000
Common stock issued for services in October 2011 through January 2012, valued at \$0.65/share to \$2.70/share Options issued for services in August 2010, vested during	1,406	1 -	1,606 38,194	- -	<del>-</del>	<del>-</del>			1,607 38,194

2012, valued at \$1.31/share Options issued for services in December 2010, vested									
during 2012, valued at \$1.14/share Warrants issued for services in April 2011,	-	-	85,290	-	-	-	-	-	85,290
vested during 2012, valued at \$0.98/share Options issued for services in May 2011,	-	-	36,605	-	-	-	-	-	36,605
vested during 2012, valued at \$0.97/share Options issued for services in August 2011,	-	-	48,510	-	-	-	-	-	48,510
vested during 2012, valued at \$0.82/share Options issued for services in November	-	-	41,156	-	-	-	-	-	41,156
2011, vested during 2012, valued at \$0.53/share Options issued for services in December	-	-	26,304	-	-	-	-	-	26,304
2011, vested during 2012, valued at \$0.82/share Warrants issued for services in December	- -	- -	51,392 157,127	- -	- -	-	- -	-	51,392 157,127

2011, vested during 2012, valued at \$1.05/share Options issued for services in March 2012, vested during									
2012, valued at \$1.37/share Options issued for services in March 2012, vested during	-	-	139,755	-	-	-	-	-	139,755
2012, valued at \$1.37/share Warrants issued for services in March 2012, vested during 2012, valued	-	-	42,227	-	_	-	-	-	42,227
at \$1.37/share Options issued for services in May 2012, vested during 2012, valued	-	-	13,709	-		-	-	-	13,709
at \$1.23/share Warrants issued for services in May 2012, vested during 2012, valued	-	-	462,455	-	_	-	-	-	462,455
at \$0.97/share Options issued for services in June 2012, vested during 2012, valued	-	-	55,648	-		-	-	-	55,648
at \$0.73/share Options issued for services in August 2012, vested during	-	-	56,568 15,611	-		-	-	-	56,568 15,611

2012, valued at \$0.74/share Options issued for services in August 2012, vested during									
2012, valued at \$0.75/share Warrants issued for services in December 2012, vested during 2012,	-	-	7,137	-		-	-	-	7,137
valued at \$0.78/share Options extended for services in November 2012, vested during 2012, valued at	-	-	28,237	-		-	-	-	28,237
\$0.27/share Options extended for services in November 2012, vested during 2012, valued at	-	-	266,710	-		-	-	-	266,710
\$0.25/share Options extended for services in November 2012, vested during 2012, valued at	-	-	25,420	-	_	-	-	-	25,420
\$0.24/share Options extended for services in November 2012, vested during 2012, valued at	-	-	60,283	-		-	-	-	60,283
\$0.29/share Options extended for	-	-	309,049 29,375	-	- -	-	- -	-	309,049 29,375

services in November 2012, vested during 2012, valued at \$0.29/share Options extended for services in November 2012, vested									
during 2012, valued at \$0.26/share Options extended for services in	-	-	39,270	-	-	-	-	- 39,	,270
November 2012, vested during 2012, valued at \$0.30/share Options extended for services in November	-	-	29,529	-	-	-	-	- 29,	,529
2012, vested during 2012, valued at \$0.28/share Net loss for the year ending December 31, 2012	-	- -	42,195	-	-	- -	- - (4 <sup>4</sup>	- 42, 556,538) (4,556,	,195 538)
BALANCE AT DECEMBER 31, 2012	50,160,758	50,161 3	\$ 2,042,751	\$	\$	\$	\$	\$ \$ \$16,039) 3,661,	

The accompanying notes are an integral part of these financial statements.

### LIGHTWAVE LOGIC, INC.

(A Development Stage Company)

### STATEMENTS OF CASH FLOW

### FOR YEARS ENDING DECEMBER 31, 2012 AND 2011 AND

### FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE) TO DECEMBER 31, 2012

	Cumulative Since Inception	For the Year Ending December 31, 2012	For the Year Ending December 31, 2011	
CASH FLOWS FROM OPERATING ACTIVITIES				
NY . 1	\$	5	\$	
Net loss	(20, 416, 020)	(4.55(.520)	(2.492.622)	
A direction and the managed larget large to most each	(28,416,039)	(4,556,538)	(3,482,622)	
Adjustment to reconcile net loss to net cash				
used in operating activities	4 202 456			
Amortization of deferred charges	4,392,456	-	-	
Amortization of prepaid expenses Warrants issued for services	75,000 4,058,773	291,326	519,441	
Stock options issued for services	6,789,808	1,816,430	882,640	
Common stock issued for services and fees	1,456,291	132,420	207,929	
	1,430,291	132,420	201,929	
Purchase right agreement amortization Depreciation and amortization of patents	222,644	79,217	35,394	
Realized gain on investments	(3,911)	19,211	33,394	
Realized gain on disposal of assets	(637)	-	-	
(Increase) decrease in assets	(037)	-	-	
Receivables	(30,461)			
Prepaid expenses and other current assets	(89,975)	(48,219)	32,433	
Increase (decrease) in liabilities	(69,973)	(40,219)	32,433	
Accounts payable	229,299	(43,449)	83,374	
Accounts payable and accrued expenses- related parties	9,768	(14,610)	14,618	
Accrued expenses	35,790	(25,039)	24,422	
rectued expenses	33,170	(23,037)	27,722	
Net cash used in operating activities	(11,139,136)	(2,368,462)	(1,682,371)	
CASH FLOWS FROM INVESTING ACTIVITIES Cost of intangibles Proceeds from sale of available for sale securities	(523,035) 203,911	(83,248)	(93,778)	

Proceeds from receipt of note receivable Purchase of available for sale securities Purchase of equipment, furniture and leasehold	100,000 (200,000)	-	- -
improvements	(451,879)	(265,634)	(17,894)
Net cash used in provided by investing activities	(871,003)	(348,882)	(111,672)
CASH FLOWS FROM FINANCING ACTIVITIES			
Issuance of common stock, private placement	7,495,524	-	1,000,000
Common stock rescinded, private placement	(200,000)	-	-
Issuance of common stock, exercise of options and warrants	2,021,404	444,400	_
Issuance of common stock, exercise of purchase right			
agreement	45,138	-	-
Issuance of common stock, institutional investor	5,049,999	4,849,999	200,000
Repayment of notes payable	(14,970)	-	-
Proceeds from subscription receivable	19,000	-	-
Advances to stockholders	(4,933)	-	-
Proceeds from convertible notes	529,000	-	-
Advances from officers	1,498	-	-
Net cash provided by financing activities	14,941,660	5,294,399	1,200,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	2,931,521	2,577,055	(594,043)
CASH AND CASH EQUIVALENTS - BEGINNING OF			
PERIOD	5,358	359,824	953,867
	\$ \$	5	\$
CASH AND CASH EQUIVALENTS - END OF PERIOD	2,936,879	2,936,879	359,824

The accompanying notes are an integral part of these financial statements.

### LIGHTWAVE LOGIC, INC.

(A Development Stage Company)

### STATEMENTS OF CASH FLOW

### FOR YEARS ENDING DECEMBER 31, 2012 AND 2011 AND

## FOR THE PERIOD JANUARY 1, 2004 (INCEPTION OF DEVELOPMENT STAGE) TO DECEMBER 31, 2012

	Cumulative Since	For the Year Ending December 31,	For the Year Ending	
	Inception	2012	December 31, 2011	
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION				
CASH PAID DURING THE PERIOD FOR:	\$	\$	\$	
Interest	23,341	109	288	
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES				
	\$	\$	\$	
Common stock issued in exchange for deferred charges	3,142,400	-	-	
	\$	\$	\$	
Warrants issued in exchange for deferred charges	1,581,056		-	
	\$	\$	\$	
Common stock issued as settlement for accounts payable	74,708		-	
	\$	\$	\$	
Accrued interest contributed as capital	35,624		-	

	\$ \$	\$	
Common stock issued in the conversion of notes payable	529,000	-	-
	\$ \$	\$	
Acquisition of automobile through loan payable	24,643	-	-
Common stock issued upon exercise of a warrant	\$ \$	\$	
in exchange for receivable	75,000	-	-
	\$ \$	\$	
Insurance company pay off of note payable	9,673	-	-
	\$ \$	\$	
Receivable for issuance of common stock	210,001	-	-
	\$ \$	\$	
Contribution of officer accrued payroll	52,129	-	-
	\$ \$	\$	
Common stock issued for prepaid expense	75,000	-	-

The accompanying notes are an integral part of these financial statements.

### LIGHTWAVE LOGIC, INC.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

#### NOTE 1- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### **History and Nature of Business**

Lightwave Logic, Inc., formerly Third-Order Nanotechnologies, Inc., formerly PSI-Tec Holdings, Inc., formerly Eastern Idaho Internet Service, Inc. (the Company) was organized under the laws of the State of Nevada in 1997. The Company was engaged in the business of marketing internet services until June 30, 1998, at which time the principal assets of the business were sold and operations were discontinued. The Company was inactive until the acquisition of PSI-TEC Corporation (PSI-TEC) on July 14, 2004, at which time the name was changed to PSI-TEC Holdings, Inc.

#### **Development Stage**

PSI-TEC was incorporated in 1995 under the laws of the State of Delaware. PSI-TEC primarily conducted research for the United States Government under a contract, which expired in 2003. Beginning January 1, 2004, PSI-TEC was engaged in the development of electro-optic polymers for application in the electro-optic device markets. PSI-TEC is considered a development stage company as defined in Financial Accounting Standards Board Accounting Standards Codification (FASB ASC) 915 Development Stage Entities from the inception of the development stage on January 1, 2004.

#### Merger

On July 14, 2004, the Company acquired PSI-TEC. Under the terms of the merger agreement, the stockholders of PSI-TEC received 15,600,000 shares of common stock in exchange for its 2,206,280 shares. Following the merger, the Company changed its name to PSI-TEC Holdings, Inc. Under accounting principles generally accepted in the United States, the share exchange is considered to be a capital transaction in substance rather than a business combination. That is, the share exchange is equivalent to the issuance of stock by PSI-TEC Holdings, Inc. for the net monetary assets of PSI-TEC, accompanied by a recapitalization, and is accounted for as a change of capital structure. Accordingly, the accounting for the share exchange was identical to that resulting from a reverse acquisition, except no goodwill was recorded. Under reverse takeover accounting, the post-reverse acquisition comparative historical financial statements of the legal acquirer, PSI-TEC Holdings, Inc., are those of the legal acquiree, PSI-TEC, which is

considered to be the accounting acquirer. On October 20, 2006, PSI-TEC Holdings, Inc. and PSI-TEC merged and changed its name to Third-Order Nanotechnologies, Inc. On March 10, 2008, Third-Order Nanotechnologies, Inc. changed its name to Lightwave Logic, Inc.

#### **Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Although these estimates are based on management s best knowledge of current events and actions the Company may undertake in the future, actual results could differ from the estimates.

### **Cash Equivalents**

For the purposes of the statement of cash flows, the Company considers all highly liquid instruments with maturities of three months or less at the time of purchase to be cash equivalents.

F-12

# Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K LIGHTWAVE LOGIC, INC.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

#### NOTE 1- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### Concentration of Credit Risk

Certain financial instruments potentially subject the Company to concentrations of credit risk. These financial instruments consist primarily of cash. At December 31, 2012, the Company did not have deposits with a financial institution that exceed the FDIC deposit insurance coverage.

#### **Property and Equipment**

Equipment is stated at cost. Depreciation is principally provided by use of straight-line methods for financial and tax reporting purposes over the estimated useful lives of the assets, generally 5 years. When property is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the Income Statement.

#### **Intangible Assets**

Definite-lived intangible assets are stated at cost. Patents are amortized over their estimated useful lives, generally 20 years. When certain patent applications are abandoned by the Company for claims that are covered by patents already granted to the Company, the cost of patent applications and accumulated amortization are removed from the accounts and the resulting expense is reflected in the Income Statement.

#### **Fair Value of Financial Instruments**

The Company s financial instruments consist of cash, accounts payable and accrued expenses. The carrying values of cash, accounts payable and accrued expenses approximate fair value because of their short maturities.

#### **Income Taxes**

The Company follows FASB ASC 740, Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.

#### Loss Per Share

The Company follows FASB ASC 260, Earnings per Share, resulting in the presentation of basic and diluted earnings per share. Because the Company reported a net loss in 2012 and 2011, common stock equivalents, including stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and dilutive loss per share were the same.

#### **Recoverability of Long Lived Assets**

The Company follows FASB ASC 360 Property, Plant, and Equipment . Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the excess of the asset s carrying amount.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

#### NOTE 1- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### **Comprehensive Income**

The Company follows FASB ASC 220.10, Reporting Comprehensive Income. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income, comprehensive income (loss) is equal to net loss.

#### **Recently Adopted Accounting Pronouncements**

As of December 31, 2012 and for the year then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company s financial statements.

#### **Recently Issued Accounting Pronouncements Not Yet Adopted**

As of December 31, 2012, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company s financial statements.

#### NOTE 2 MANAGEMENT S PLANS

The Company currently has a cash position of approximately \$3,300,000. Based upon the current cash position and expenditures of approximately \$250,000 per month and no debt service, management believes the Company has sufficient funds currently to finance its operations through April 2014. In May 2011, the Company signed an agreement with an institutional investor to sell up to \$20 million of common stock. Under the agreement subject to certain conditions and at the Company's sole discretion, the institutional investor has committed to invest up to \$20 million in the Company's common stock over a 30-month period with the remaining available amount of \$13,950,003. The Company filed a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares that may be issued to the institutional investor. The institutional investor is obligated to make purchases as the Company directs in accordance with the agreement that may be terminated by the Company at any time, without cost or penalty. Sales of shares will be made in specified amounts and at prices that are based upon the market prices of the Company's common stock. Additional funding may also be provided by the exercise of outstanding warrants of up to approximately \$1,500,000 through September 2013. With additional capital raised, the Company expects to achieve a level of revenues attractive enough to fulfill its development activities and achieve a level of revenue adequate to support the Company s business model. The Company continues to develop and test its next generation Electro-Optic and third-order material platform to support and cultivate potential customers, strategic partners and develop photonic devices. Management believes the Company s initial revenue stream will be in prototype devices, application and non-recurring engineering charges, and material charges for specialty non-linear application prior to moving into full commercialization and production.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 3 PROPERTY AND EQUIPMENT

Equipment consists of the following:

	December 31, 2012		December 31, 2011	
	\$		\$	
Office equipment		12,741		12,816
Lab equipment		388,521		169,028
Furniture		4,061		3,494
Leasehold improvements		28,134		5,368
_		433,457		190,706
Less: Accumulated depreciation		132,463		101,955
	\$		\$	
		300,994		88,751

Depreciation expense for the years ending December 31, 2012 and 2011 was \$53,391 and \$26,711.

#### NOTE 4 INTANGIBLE ASSETS

This represents legal fees and patent fees associated with the prosecution of patent applications. The Company has recorded amortization expenses on the Spacer and Chromophore patents granted by the United States Patent and Trademark Office in February 2011, April 2011 and September 2012, which are amortized over its legal life of 20 years and Chromophore patent granted by the Australian Patent Office in November 2012 which is amortized over its legal life of 20 years. Certain patent applications are abandoned by the Company when the claims are covered by

patents already granted to the Company. Patent applications abandoned have been written off at full capitalized cost. No amortization expense has been recorded on the remaining patent applications since patents have yet to be granted. Once the patents are granted, the cost of the patents will be amortized over their legal lives, which is generally 20 years.

Patents consists of the following:

	Decen	nber 31, 2012	Decen	nber 31, 2011
	\$		\$	
Patents Less: Accumulated amortization		509,360 20,834		439,787 8,683
	\$		\$	
		488,526		431,104

Amortization expense for the years ending December 31, 2012 and 2011 was \$12,151 and \$8,683. Expense for abandoned patents for claims covered by patents already granted to the Company are recorded in research and development expenses and for the years ending December 31, 2012 and 2011 were \$13,675 and \$0.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

#### NOTE 5 COMMITMENTS

The Company is obligated under operating leases for laboratory space expiring June 2013 and April 2014.

Aggregate minimum future lease payments under the operating leases are as follows:

YEAR ENDING

DECEMBER 31,	AN	IOUNT
	\$	
2013		74,194
2014		23,276

Rent expense approximating \$53,563 and \$9,910 is included in research and development expenses for the years ended December 31, 2012 and 2011.

## NOTE 6 INCOME TAXES

As discussed in Note 1, the Company utilizes the asset and liability method of accounting for income taxes in accordance with FASB ASC 740.

The income tax benefit (provision) consists of the following:

	203	12	2011
	\$	\$	
Current Deferred Change in valuation allowance	(:	563,000) 576,000) 139,000	(895,000) (602,000) 1,497,000
	\$	\$	

The reconciliation of the statutory federal rate to the Company s effective Income tax rate is as follows:

	2012		2011	
In come too bonefit at II C	Amount	%	Amount	%
Income tax benefit at U.S.	\$		\$	
federal income tax rate	(1,549,000)	(34)	(1,184,000)	(34)
State tax, net of federal tax effect	(410,000)	(9)	(313,000)	(9)
Non-deductible share-based compensation	(180,000)	(4)	-	_
Change in valuation allowance	2,139,000	47	1,497,000	43
	\$		\$	
	_	_	_	_

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

#### NOTE 6 INCOME TAXES (CONTINUED)

The components of deferred tax assets as of December 31, 2012, and December 31, 2011 are as follows:

	20	12	2011
	\$	\$	
Deferred tax asset for NOL carryforwards	8,	647,000	7,084,000
Share-based compensation	2,	966,000	2,390,000
Accrued expenses		17,000	17,000
Valuation allowance	(11,	630,000)	(9,491,000)
	\$	\$	
		_	_

The valuation allowance for deferred tax assets as of December 31, 2012 and 2011 was \$11,630,000 and \$9,491,000, respectively. The change in the total valuation for the years ended December 31, 2012 and 2011 was an increase of \$2,139,000 and \$1,497,000, respectively. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the net operating losses and temporary differences become deductible. Management considered projected future taxable income and tax planning strategies in making this assessment. The value of the deferred tax assets was offset by a valuation allowance, due to the current uncertainty of the future realization of the deferred tax assets.

As of December 31, 2012, the Company had net operating loss carry forwards of approximately \$20,100,000, expiring through the year ending December 31, 2032. This amount can be used to offset future taxable income of the Company.

The timing and manner in which the Company can utilize operating loss carryforwards in any year may be limited by provisions of the Internal Revenue Code regarding changes in ownership of corporations. Such limitation may have an impact on the ultimate realization of its carryforwards and future tax deductions.

On January 1, 2007, the Company adopted FASB ASC 740.10, which provides guidance for the recognition and measurement of certain tax positions in an enterprise s financial statements. Recognition involves a determination of whether it is more likely than not that a tax position will be sustained upon examination with the presumption that the tax position will be examined by the appropriate taxing authority having full knowledge of all relevant information. The adoption of FASB ASC 740.10 did not require an adjustment to the Company s financial statements.

The Company s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of January 1, 2012, the Company had no unrecognized tax benefits and no charge during 2012, and accordingly, the Company did not recognize any interest or penalties during 2012 related to unrecognized tax benefits. There is no accrual for uncertain tax positions as of December 31, 2012.

The Company files U.S. income tax returns and a state income tax return. With few exceptions, the U.S. and state income tax returns filed for the tax years ending on December 31, 2009 and thereafter are subject to examination by the relevant taxing authorities.

F-17

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY

#### **Preferred Stock**

Pursuant to our Company s Articles of Incorporation, our board of directors is empowered, without stockholder approval, to issue series of preferred stock with any designations, rights and preferences as they may from time to time determine. The rights and preferences of this preferred stock may be superior to the rights and preferences of our common stock; consequently, preferred stock, if issued could have dividend, liquidation, conversion, voting or other rights that could adversely affect the voting power or other rights of the common stock. Additionally, preferred stock, if issued, could be utilized, under special circumstances, as a method of discouraging, delaying or preventing a change in control of our business or a takeover from a third party.

#### **Common Stock and Warrants**

The stockholders deficit at January 1, 2004 has been retroactively restated for the equivalent number of shares received in the reverse acquisition at July 14, 2004 (Note 1) after giving effect to the difference in par value with the offset to additional paid-in-capital.

In July 2004, the Company issued 1,600,000 shares of its common stock for professional services valued at \$256,000, fair value.

In August 2004, the Company issued 637,500 shares of its common stock for professional services valued at \$75,000, fair value.

In December 2004, the Company converted a note payable of \$30,000 into 187,500 shares of common stock at a conversion price of \$0.16 per share.

In April 2005, the Company issued 4,000,000 shares of its common stock in a private placement for proceeds of \$1,000.000.

On May 4, 2005, the Company converted the notes payable of \$499,000 into 3,118,750 shares of common stock at a conversion price of \$0.16 per share. An unpaid note payable in the amount of \$6,500 has been reflected as a subscription receivable. During 2006, the Company deemed this \$6,500 outstanding subscription receivable to be uncollectible.

During August 2005, the Company issued 210,000 shares of common stock for professional services rendered valued at \$585,500, fair value. Consulting expense of \$375,500 was recognized during 2005, and at December 31, 2005, the remaining balance of \$210,000 is reflected as a deferred charge on the balance sheet. During 2006, consulting expense of \$210,000 was recognized. This agreement ended in May 2006.

In August 2005, in conjunction with a management services contract with a related party, the Company issued 200,000 shares of common stock valued at \$584,000. Management expense of \$265,455 was recognized during 2005, and at December 31, 2005, the remaining balance of \$318,545 is reflected as a deferred charge in a contra-equity account. During 2006, management expense of \$318,545 was recognized. This agreement ended in June 2006.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

During May 2005, the Company issued Stock Purchase Warrants to purchase 100,000 shares of common stock at an exercise price of \$2.10 in exchange for consulting services. The warrants are exercisable until May 2008 and vest as follows: 50,000 shares during the first year of the agreement, 25,000 shares during the second year of the agreement, and 25,000 shares during the third year. In accordance with the fair value method, the Company used the Black-Scholes model to calculate the grant-date fair value, with the following assumptions: no dividend yield, expected volatility of 60%, risk-free interest rate of 3.8% and expected life of option of three years. The fair market value of the warrants was \$113,250. In accordance with the fair value method as described in accounting requirements of FASB ASC 718 Stock Compensation, the Company recognized consulting expense of \$37,000 in 2005. This warrant was cancelled during 2006.

During September 2005, the Company issued Stock Purchase Warrants to purchase 100,000 shares of common stock at an exercise price of \$2.00 in exchange for consulting services. The warrants expire in September 2008 and vest as follows: 50,000 shares during the first year of the agreement, 25,000 shares during the second year of the agreement, and 25,000 shares during the third year of the agreement. In accordance with the fair value method, the Company used the Black-Scholes model to calculate the grant-date fair value, with the following assumptions: no dividend yield, expected volatility of 60%, risk-free interest rate of 3.8% and expected life of option of three years. The fair market value of the warrants was \$145,100. The Company recognized consulting expense of \$27,014, \$36,370, \$66,500 and \$24,200 for the years ended December 31, 2008, 2007, 2006 and 2005 in conjunction with this agreement. These warrants expired in September 2008.

On October 15, 2005, the Company issued Stock Purchase Warrants to purchase 30,000 shares of common stock at an exercise price of \$1.40 in exchange for consulting services. The warrants expire in October 2006 and are exercisable immediately. In accordance with the fair value method, the Company used the Black-Scholes model to calculate the grant-date fair value, with the following assumptions: no dividend yield, expected volatility of 60%, risk-free interest rate of 4.15% and expected life of option of one year. The fair market value of the warrants was \$15,900. In

accordance with the fair value method as described in accounting requirements of FASB ASC 718 Stock Compensation, the Company recognized consulting expense of \$15,900 during 2005. These warrants expired in October 2006.

In December 2005, in conjunction with a consulting contract, the Company issued Stock Purchase Warrants to purchase 300,000 shares of common stock at an exercise price of \$0.25 per share valued at \$435,060, fair value. The warrants expire in December 2007 and were exercisable immediately. In accordance with the fair value method, the Company used the Black-Scholes model to calculate the grant-date fair value, with the following assumptions: no dividend yield, expected volatility of 60%, risk-free interest rate of 4.41% and expected life of option of two years. In accordance with the fair value method as described in accounting requirements of FASB ASC 718 Stock Compensation, the Company recognized consulting expense of \$199,435, and at December 31, 2005, the remaining balance in deferred charges amounted to \$235,625. The 300,000 warrants were fully exercised on December 31, 2005 for \$75,000. The Company recognized \$18,128 and \$217,497 in consulting expense in conjunction with this agreement for the years ended December 31, 2007 and 2006, which was cancelled during 2007.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

During 2006, the Company issued 850,000 shares of common stock and warrants to purchase 425,000 shares of common stock for proceeds of \$425,000 in accordance to a private placement memorandum amended December 18, 2006. Pursuant to the terms of the amended offering, up to 20 units were offered at the offering price of \$50,000 per unit, with each unit comprise of 100,000 shares and a warrant to purchase 50,000 shares of common stock at \$0.50 per share. In November 2007, 400,000 shares of common stock and warrants to purchase 200,000 shares of common stock were rescinded. As of December 31, 2008, warrants to purchase 210,000 shares of common stock were fully exercised for proceeds of \$105,000, and warrants to purchase 15,000 shares expired.

During February 2006, the Company issued 300,000 shares of common stock for professional services rendered valued at \$270,000, fair value. The Company recognized consulting expense of \$16,875 and \$118,125 and legal expense of \$16,875 and \$118,125 during 2007 and 2006. The contracts expired during 2007. The legal services were provided by a related party.

During May 2006, the Company issued 400,000 shares of common stock for professional services rendered valued at \$620,000, fair value. The Company recognized consulting expense of \$258,333 and \$361,667 during 2007 and 2006, and at December 31, 2006. The contracts expired during 2007.

During June 2006, the Company issued 25,000 shares of common stock to a related party for professional services rendered valued at \$36,250, fair value. The Company recognized legal expense of \$16,615 and \$19,635 during 2007 and 2006, and at December 31, 2006. The contracts expired during 2007.

During November 2006, the Company issued 60,000 shares of common stock for professional services valued at \$29,400, fair value. The Company recognized investor relations expense of \$25,480 and \$3,920 during 2007 and 2006. The contract expired during 2007.

In June 2006, in conjunction with an addendum to an existing consulting contract effective December 2005, the Company issued Stock Purchase Warrants to purchase 300,000 shares of common stock at an exercise price of \$0.25 per share. The warrants expire in June 2008 and were exercisable immediately. In accordance with the fair value method, the Company used the Black-Scholes model to calculate the grant-date fair value, with the following assumptions: no dividend yield, expected volatility of 186%, risk-free interest rate of 4.41% and expected life of option of two years. The fair market value of the warrants was \$465,996. During 2007 and 2006, the Company recognized consulting expense of \$330,948 and \$135,048 in conjunction with this agreement. The contract was cancelled during 2007. The 300,000 warrants were fully exercised on March 12, 2008 for proceeds of \$75,000.

During 2006, the Company cancelled a warrant issued during May 2005 to purchase 100,000 shares of the Company s common stock at an exercise price of \$2.10, and issued an option to purchase 500,000 shares of the Company s common stock at an exercise price of \$1 per share and the same option s expiration and vesting terms were modified during November 2006. This option expired in June 2007. The incremental cost of the modified option was \$394,030 and will be expensed over the vesting terms. The Company recognized \$17,589 and \$406,215 as a consulting expense in 2007 and 2006, which includes \$337,290 of the incremental cost of the modified option.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

During February 2006, the Company awarded an employee with an option to purchase 200,000 shares of common stock at an exercise price of \$1.00 per share under the 2005 Employee Stock Option Plan. These options were valued at \$217,628 using the Black-Scholes Option Pricing Formula. The employee compensation expense recognized during 2007 and 2006 is \$43,757 and \$22,673. In June 2007, the employee was terminated and the vesting ceased. After September 2007, the vested options expired.

During 2006, the Company recognized contributed capital of \$35,624 related to the conversion of accrued interest payable.

During 2006, the Company deemed a May 2005 outstanding subscription receivable of \$6,500 to be uncollectible.

During 2007, the Company issued 2,482,000 shares of common stock and warrants to purchase 1,241,000 shares of common stock for proceeds of \$1,241,000 in accordance to a private placement memorandum amended December 18, 2006. Pursuant to the terms of the amended offering, up to 20 units were offered at the offering price of \$50,000 per unit, with each unit comprised of 100,000 shares and a warrant to purchase 50,000 shares of common stock at \$0.50 per share. For the six month ending June 30, 2009, the remaining 600,000 outstanding warrants expired.

During 2007, the Company issued 1,767,540 shares of common stock and warrants to purchase 883,770 shares of common stock for proceeds of \$1,060,524 in accordance to a private placement memorandum issued on October 3, 2007. Pursuant to the terms of the offering, up to 20 units were offered at the purchase price of \$60,000 per unit, with each unit comprised of 100,000 shares and a warrant to purchase 50,000 shares of common stock at \$1.00 per share.

During 2009 and 2008, 416,000 and 82,770 warrants were exercised, respectively. For the year ending December 31, 2009, the remaining 385,000 outstanding warrants expired.

During 2007, as previously described, a shareholder that was issued 400,000 shares of the Company s common stock and a warrant to purchase 200,000 shares of common stock at \$0.50 per share rescinded his shares and warrant.

During February 2007, the Company issued 151,785 shares of common stock for investor relations services valued at \$106,250, fair value, which was recorded as a deferred charge and amortized over one year, the term of the services contract. During 2007, the Company recognized \$97,396 in investor relations expense. During 2008, the Company recognized \$8,854 in investor relations expense. This contract expired in February 2008.

During February 2007, the Company terminated its then CEO. The option to purchase 56,000 shares of common stock that was recorded as deferred charges of \$42,730 were not vested and were forfeited. The option to purchase 444,000 shares of common stock that were vested expired during 2007.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

During March 2007, the Company issued 1,000,000 shares of common stock to a related party for management consulting services valued at \$580,000, fair value. During April 2007, the Company issued 500,000 warrants as an addendum to the original contract for management consulting services valued at \$348,000, fair value. This contract was recorded as a contra-equity deferred charges account and is amortized over one year, the term of the contract. Management consulting expense recognized during 2008 and 2007 is \$154,667 and \$773,333. This contract was renewed in March, 2008. In December 2010, the warrant was partially exercised to purchase 100,000 shares of common stock for proceeds of \$25,000. In April 2012, the warrant was exercised to purchase the remaining 400,000 shares of common stock for proceeds of \$100,000.

During April 2007, the Company issued 100,000 shares of common stock for legal services to a related party valued at \$35,000, fair value, to settle \$29,708 of accounts payable and as payment for \$5,292 of legal services incurred in April 2007.

During October 2007, the Company issued 150,000 shares of common stock for investor relations services valued at \$102,000, fair value to a related party. During 2007 the Company recognized \$102,000 in investor relation expense.

During October 2007, the Company issued 150,000 shares of common stock for investor relations services valued at \$135,000, fair value. During 2007, the Company recognized \$135,000 in investor relations expense.

During November 2007, the Company issued 400,000 shares of common stock under the 2007 Stock Option Plan to the acting Chief Executive Officer for services rendered valued at \$288,000, fair value. The Company recognized

\$288,000 in consulting expense during 2007.

During March 2007, the Company issued a warrant to purchase 100,000 shares of common stock for consulting services at an exercise price of \$0.25 per share. The warrant was valued at \$63,065 using the Black-Scholes Option Pricing Formula and expensed over the life of the contract associated with the consulting services, which is one year. The consulting expense recognized during 2008 and 2007 is \$10,885 and \$52,180. In April 2010, the warrant was exercised to purchase 100,000 shares of common stock for proceeds of \$25,000.

During April 2007, the Company issued warrants to purchase 900,000 shares of common stock for consulting services at an exercise price of \$0.25 per share. The warrants were valued at \$604,416 using the Black-Scholes Option Pricing Formula and expensed over the life of the contracts associated with the consulting services, which is one year. The consulting expense recognized during 2008 and 2007 is \$170,451 and \$433,966. In July 2008, the warrant was partially exercised to purchase 20,000 shares of common stock for proceeds of \$5,000. In April 2010, the warrant was partially exercised to purchase 380,000 shares of common stock for proceeds of \$95,000. In April 2012, the warrant was exercised to purchase the remaining 500,000 shares of common stock for proceeds of \$125,000.

During May 2007, the Company issued a warrant to purchase 150,000 shares of common stock for consulting services at an exercise price of \$0.25 per share. The warrant was valued at \$84,390 using the Black-Scholes Option Pricing Formula and expensed over the life of the contract associated with the consulting services, which is one year. The consulting expense recognized during 2008 and 2007 is \$31,444 and \$52,946. In April 2010, the warrant was exercised to purchase 150,000 shares of common stock for proceeds of \$37,500.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

**Common Stock and Warrants (Continued)** 

During October 2007, the Company issued a warrant to purchase 100,000 shares of common stock at a purchase price of \$0.25 per share for accounting services rendered. The warrant was valued at \$61,449 using the Black-Scholes Option Pricing Formula expiring in two years. The Company recognized \$61,449 in accounting expense during 2007. For the year ending December 31, 2009, the warrant expired.

During October 2007, the Company issued a warrant to purchase 67,200 shares of common stock at a purchase price of \$0.25 per share for consulting services rendered. The warrant was valued at \$52,292 using the Black-Scholes Option Pricing Formula. During 2007, the Company recognized \$52,292 in consulting expense. In October 2010, the warrant was exercised to purchase 67,200 shares of common stock for proceeds of \$16,800.

During December 2007, the Company issued a warrant to purchase 25,000 shares of common stock at a purchase price of \$0.50 per share for accounting services rendered. The warrant was valued at \$13,646 using the Black-Scholes Option Pricing Formula and expensed over the life of the contract, which is one year. The Company recognized \$12,487 and \$1,159 in consulting expense during 2008 and 2007. In June 2010, the warrant was exercised to purchase 25,000 shares of common stock for proceeds of \$12,500.

During November 2007, under the 2007 Employee Stock Option Plan, the Company issued options to purchase 1,752,000 shares of common stock at a purchase price of \$0.72 per share. The options were valued at \$1,045,077 using the Black-Scholes Option Pricing Formula. The options expire in 5 years with 146,000 shares vesting each quarter from date of grant. During 2008, an option to purchase 750,000 shares of common stock, of which 125,000 shares were vested, forfeited. In November 2012, the remaining options were extended to November 2014. The option extensions were valued at \$266,710 using the Black-Scholes Option Pricing Formula and vest immediately. The options are expensed over the vesting terms. The consulting expense recognized during 2011, 2010, 2009, 2008 and 2007 is \$0, \$174,866, \$199,233, \$286,803 and \$41,653. For the year ending December 31, 2012 and 2011, the Company recognized \$266,710 and \$0 of expense. The options are still outstanding as of December 31, 2012.

In January 2008, under the 2007 Employee Stock Option Plan, the Company issued an option to purchase 100,000 shares of common stock at a purchase price of \$0.72 per share. The option was valued at \$59,490, fair value, using the Black-Scholes Option Pricing Formula vesting 25,000 immediately and the remaining in annual equal installments of 25,000. In November 2012, the option was extended to January 2015. The option extension was valued at \$25,420 using the Black-Scholes Option Pricing Formula and vest immediately. The option is expensed over the vesting terms. The expense recognized during 2011, 2010, 2009 and 2008 is \$285, \$14,873, \$13,582 and \$30,750. For the year ending December 31, 2012 and 2011, the Company recognized \$25,420 and \$285 of expense. The option is still outstanding as of December 31, 2012.

During 2008, the Company issued 690,001 shares of common stock and warrants to purchase 345,001 shares of common stock for proceeds of \$414,000 in accordance to a private placement memorandum issued on October 3, 2007. Pursuant to the terms of the offerings, up to 25 units were offered at the purchase price of \$60,000 per unit, with each unit comprised of 100,000 shares and a warrant to purchase 50,000 shares of common stock at \$1.00 per share. During 2009 and 2008, the warrant was partially exercised to purchase 25,834 and 20,000 shares of common stock for proceeds of \$25,834 and \$20,000. In April 2010, the warrant was partially exercised to purchase 282,500 shares of common stock for proceeds of \$282,500. During the six month ending June 30, 2010, the remaining warrants to purchase 16,667 shares of common stock expired.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

## NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

### **Common Stock and Warrants (Continued)**

During March 2008, the Company issued a warrant to purchase 400,000 shares of common stock as an addendum to the original contract for management consulting services provided by a related party, valued at \$332,000, fair value using Black-Scholes Option Pricing Formula, vesting immediately. This contract was recorded as a contra-equity deferred charges account and is amortized over one year beginning February 28, 2008, the term of the contract. For the year ending December 31, 2009 and 2008, the Company recognized \$55,330 and \$276,670 of management consulting expense. In January 2009, the warrant was fully exercised to purchase 400,000 shares of common stock for proceeds of \$400.

During March 2008, the Company issued 100,000 shares of common stock for legal services to a related party valued at \$75,000, fair value. The Company recognized \$75,000 of legal expense for the year ending December 31, 2008.

During April 2008, the Company issued a warrant to purchase 600,000 shares of common stock at a purchase price of \$0.73 per share for consulting services rendered. The warrant was valued at \$976,193, fair value, using the Black-Scholes Option Pricing Formula, vesting immediately. For the year ended December 31, 2008, the Company recognized \$976,193 in consulting expense. The warrant is still outstanding as of December 31, 2012.

In July 2008, the Company issued options to purchase 200,000 shares of common stock at a purchase price of \$1.75 per share to members of the board of directors, under the 2007 Employee Stock Option Plan. Using the Black-Scholes Option Pricing Formula, the options were valued at \$296,247, fair value, vesting 50,000 immediately and the remaining in annual equal installments of 50,000 over the next three years. In November 2012, the option was extended to July 2015. The option extension was valued at \$58,904 using the Black-Scholes Option Pricing Formula

and vest immediately. The expense is being recognized based on vesting terms over a three year period. The expense recognized during 2011, 2010, 2009 and 2008 is \$39,829, \$74,061, \$67,840 and \$114,519. For the year ending December 31, 2012 and 2011, the Company recognized \$58,904 and \$39,829 of expense. The options are still outstanding as of December 31, 2012.

In August 2008, under the 2007 Employee Stock Option Plan, the Company issued options to purchase 550,000 and 1,050,000 shares of common stock at a purchase price of \$1.42 and \$1.75 per share to members of the board of directors and the Chief Executive Officer, vesting 212,500 immediately and the remaining in annual equal installments of 112,500 over the next three years and vesting in quarterly equal installments of 87,500 commencing November 1, 2008, respectively. The options were valued at \$2,176,201, fair value, using the Black-Scholes Option Pricing Formula. In November 2012, the options were extended to August 2015 and July 2015, respectively. The option extensions were valued at \$450,797 using the Black-Scholes Option Pricing Formula and vest immediately. The options are expensed over the vesting terms. The expense recognized during 2011, 2010, 2009 and 2008 is \$383,881, \$643,812, \$623,246 and \$525,263. For the year ending December 31, 2012 and 2011, the Company recognized \$450,797 and \$383,881 of expense. The options are still outstanding as of December 31, 2012.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

In August 2008, the Company issued 200,000 shares of common stock under the 2007 Stock Option Plan to its new Chief Executive Officer as part of the employment agreement valued at \$360,000, fair value. The Company recognized \$360,000 in consulting expense for the year ending December 31, 2008.

In 2008, January through August warrant holders exercised warrants to purchase 270,000 shares at \$0.50 per share for proceeds of \$135,000.

On October 28, 2008, the Company s board of directors authorized the Company to raise up to \$600,000 of capital through an Adjusted Common Stock Offering to certain warrant holders. This offering provided eligible warrant holders with the opportunity to purchase four (4) shares of common stock for each dollar invested pursuant to their existing warrant agreement. As of December 31, 2008, warrants to purchase 641,080 shares of common stock were exercised with proceeds of \$160,270. For the three month period ending March 31, 2009, warrants to purchase 1,279,336 shares of common stock were exercised with proceeds of \$319,834. In January 2009, the term of the 2008 Adjusted Common Stock offering was extended until January 31, 2009.

In November 2008, the Company issued an option to purchase 250,000 shares of common stock under the 2007 Stock Option Plan at a purchase price of \$.65 per share to a new member of its board of directors. Using the Black-Scholes Option Pricing Formula, the options were valued at \$125,911, fair value, vesting 62,500 immediately and the remaining in annual equal installments of 62,500 over the next three years. The expense is being recognized based on vesting terms over a three year period. The expense recognized during 2011, 2010, 2009 and 2008 is \$26,648, \$31,478, \$61,346 and \$6,439. In January 2012, the option was exercised to purchase 250,000 shares of common stock for proceeds of \$162,500.

In January 2009, an employee was granted with an option to purchase up to 25,000 shares of common stock at a purchase price of \$.25 per share. Using the Black-Scholes Option Pricing Formula, the options were valued at valued at \$13,136, fair value. These options expire in 5 years and vest immediately. The expense recognized during 2009 is \$13,136. In May 2010, the option was partially exercised to purchase 15,000 shares of common stock for proceeds of \$3,750. As of December 31, 2012, options to purchase 10,000 shares of common stock are still outstanding.

During January 2009, the Company issued 100,000 shares of common stock to an officer, under the 2007 Stock Option Plan, for services rendered valued at \$58,000, fair value.

During January 2009, the Company issued 100,000 shares of common stock for legal services to a related party valued at \$25,000, to settle accounts payable for \$10,000 and \$15,000 for legal services.

During January 2009, the officers, directors, and employees of the Company were each given the right to purchase from the Company s 2007 Employee Stock Plan up to 40,000 shares of common stock at a purchase price of \$.25 per share, 400,000 shares in the aggregate, all of which were valued at \$132,058, fair value using the Black-Scholes Option Pricing Formula. The rights to purchase vested immediately. A total of 180,550 shares were purchased pursuant to the rights to purchase with total proceeds of \$35,138 and a common stock receivable of \$10,000 which was paid in May, 2009. The rights to purchase the remaining 219,450 shares expired on January 31, 2009.

(A Development Stage Company)

## NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

At December 31, 2008 the Company had accrued officer salaries and payroll taxes of \$98,205. On February 19, 2009, two officers, who are also shareholders, agreed to waive their rights to unpaid wages and salary amounting to \$52,129. Accordingly in the first quarter 2009, the accrued expense was adjusted from \$98,205 to \$42,088 with the \$52,129 treated as contributed capital and \$3,988 reversed from payroll taxes.

In February 2009, an employee was granted with an option to purchase up to 25,000 shares of common stock at a purchase price of \$.45 per share. Using the Black-Scholes Option Pricing Formula, the options were valued at valued at \$9,583, fair value. These options expire in 5 years and vest immediately. The expense recognized during 2009 is \$9,583. The options are still outstanding as of December 31, 2012.

During June 2009, in accordance to private placement memorandum, the Company issued 2,479,500 shares of common stock for proceeds of \$855,000 dated June 10, 2009. Pursuant to the terms of the offering, up to 18 units were offered at the offering price of \$50,000 per unit, with each unit comprised of 145,000 shares to purchase at \$0.34 per share.

During June 2009, the Company issued a warrant to purchase 464,000 shares of common stock at a purchase price of \$0.34 per share for accounting services rendered. The warrant was valued at \$391,342 using the Black-Scholes Option Pricing Formula, vesting 46,400 immediately and the remaining on equal monthly installments of 23,200 over the next eighteen months. The warrant expires in 5 years. The expense is being recognized based on service terms of the agreement over a twenty two month period. The expense recognized during 2010 and 2009 is \$213,459 and \$177,883. In April 2010, the warrant was partially exercised to purchase 10,000 shares of common stock for proceeds of \$3,450. In February 2012, the warrant was partially exercised to purchase 20,000 shares of common stock for proceeds of \$6,900. As of December 31, 2012, warrants to purchase 434,000 shares of common stock are still

outstanding.

In June 2009, an employee was granted with an option to purchase up to 25,000 shares of common stock at a purchase price of \$.34 per share. Using the Black-Scholes Option Pricing Formula, the options were valued at \$21,085, fair value. These options expire in 5 years and vest immediately. The expense recognized during 2009 is \$21,085. The option is still outstanding as of December 31, 2012.

During June 2009, the Company issued 145,000 shares of common stock for legal services to a related party valued at \$50,000, to settle accounts payable for \$35,000 and \$15,000 for legal services.

During June 2009, the Company issued 116,000 shares of common stock for accounting services valued at \$40,000, fair value. The Company recognized \$40,000 of accounting expense for the year ending December 31, 2009.

During July 2009, the Company issued 100,000 shares of common stock for investor relation services valued at \$75,000, fair value vesting 25,000 shares each quarter commencing July 1, 2009. The investor relation expense recognized during 2010 and 2009 is \$37,500 and \$37,500.

(A Development Stage Company)

## NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

#### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

In January 2010, the Company issued a warrant to purchase 650,000 shares of common stock at a purchase price of \$1.51 per share to a new member of its board of directors serving as the Company s full-time non-executive chair of the board of directors. Using the Black-Scholes Option Pricing Formula, the warrants were valued at \$1,188,000, fair value, vesting 162,500 immediately and the remaining in annual equal installments of 162,500 over the next three years. The warrant expires in 5 years. During 2011, the warrant to purchase 650,000 shares of common stock, of which 487,500 shares were vested, forfeited. The expense recognized during 2011 and 2010 is \$306,765 and \$580,167. The warrant to purchase 487,500 shares of common stock is still outstanding as of December 31, 2012.

In March 2010, the Company issued a warrant to purchase 150,000 shares of common stock for consulting services at an exercise price of \$0.25 per share. Using the Black-Scholes Option Pricing Formula, the warrants were valued at \$279,045, fair value, vesting immediately. The warrant expires in 3 years. The consulting expense recognized during 2011 and 2010 is \$64,983 and \$214,063. In June and July 2010, the warrant was fully exercised to purchase 150,000 shares of common stock for proceeds of \$37,500.

In June 2010, an employee was granted with an option to purchase up to 100,000 shares of common stock at a purchase price of \$1.50 per share. Using the Black-Scholes Option Pricing Formula, the options were valued at valued at \$131,075, fair value. These options expire in 5 years and vest in equal installments of 12,500 over the next two years commencing August 1, 2010. The expense recognized during 2011 and 2010 is \$65,447 and \$27,434. For the year ending December 31, 2012 and 2011, the Company recognized \$38,194 and \$65,447 of expense. The options are still outstanding as of December 31, 2012.

During 2010, the Company issued 1,500,000 shares of common stock and warrants to purchase 375,000 shares of common stock with 156,250 warrants expiring September 2011 and 218,750 warrants expiring December 2011 for

proceeds of \$1,500,000 in accordance to a private placement memorandum as amended on September 14, 2010. Pursuant to the terms of the offerings, up to 30 units were offered at the purchase price of \$50,000 per unit, with each unit comprised of 50,000 shares and a warrant to purchase 12,500 shares of common stock at \$1.25 per share. During September 2011, all warrants were extended one year expiring September 2012 and December 2012. During August 2012, all warrants were extended six months expiring March 2013 and June 2013. In January 2012, the warrant was partially exercised to purchase 40,000 shares of common stock for proceeds of \$50,000. The remaining warrants to purchase 335,000 shares of common stock at \$1.25 per share are still outstanding as of December 31, 2012.

Effective July 8, 2010, the number of shares of the Company s common stock available for issuance under the 2007 Employee Stock plan was increased from 3,500,000 to 6,500,000 shares.

During August 2010, the Company issued 4,800 shares of common stock for investor relations services valued at \$6,000, fair value. The Company recognized \$6,000 of investor relations expense for the year ending December 31, 2010.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

In November 2010, the board of directors approved a grant to employees of options to purchase up to 250,000 shares of common stock at a purchase price of \$1.00 per share. These options were granted on December 13, 2010. Using the Black-Scholes Option Pricing Formula, the options were valued at \$283,787, fair value. These options expire in 5 years with 125,000 vesting on December 13, 2010 and 125,000 vesting on June 13, 2011. The expense recognized during 2011 and 2010 is \$127,080 and \$156,707. The options are still outstanding as of December 31, 2012.

In November 2010, the board of directors approved a grant to employees of options to purchase up to 35,000 shares of common stock at a purchase price of \$1.00 per share. These options were granted on December 13, 2010. Using the Black-Scholes Option Pricing Formula, the options were valued at \$39,730, fair value. These options expire in 5 years and vest on December 13, 2010. The expense recognized during 2010 is \$39,730. The options are still outstanding as of December 31, 2012.

In November 2010, the board of directors approved a grant to three outside directors of options to purchase up to 300,000 shares of common stock at a purchase price of \$1.00 per share. These options were granted on December 13, 2010. Using the Black-Scholes Option Pricing Formula, the options were valued at valued at \$340,545, fair value. These options expire in 5 years and vest 75,000 on December 13, 2010 and the remaining in equal annual installments of 75,000 over the next three years commencing November 4, 2011. The expense recognized during 2011 and 2010 is \$85,056 and \$89,565. For the year ending December 31, 2012 and 2011, the Company recognized \$85,290 and \$85,056 of expense. The options are still outstanding as of December 31, 2012.

In November 2010, 5,000 shares of common stock were issued for investor relation services valued at \$4,650, fair value. The Company recognized \$4,650 of investor relations expense for the year ending December 31, 2010.

During December 2010, the Company issued 10,000 shares of common stock for investor relations services valued at \$12,000, fair value. The Company recognized \$12,000 of investor relations expense for the year ending December 31, 2010.

In January 2011, the Company issued a warrant to a related party to purchase 10,000 shares of common stock for legal services at an exercise price of \$1.25 per share. Using the Black-Scholes Option Pricing Formula, the warrants were valued at \$10,453, fair value. These warrants expire in 3 years and vest immediately. The expense recognized during 2011 is \$10,453. The warrants are still outstanding as of December 31, 2012.

In January 2011, the Company issued a warrant to purchase 25,000 shares of common stock for research and development at an exercise price of \$1.25 per share. Using the Black-Scholes Option Pricing Formula, the warrants were valued at \$26,132, fair value. These warrants expire in 3 years and vest immediately. The consulting expense recognized during 2011 is \$26,132. During April 2012 the warrant was voided.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

During March 2011, the Company issued 10,000 shares of common stock for investor relations expense valued at \$14,500, fair value. The Company recognized \$14,500 of investor relations expense for the year ending December 31, 2011.

During April 2011, the Company issued warrants to purchase 150,000 shares of common stock at a purchase price of \$1.18 per share for accounting services rendered commencing January 1, 2011. The warrant was valued at \$146,425 using the Black-Scholes Option Pricing Formula, vesting 37,500 immediately and the remaining on equal monthly installments of 9,375 over the next twelve months expiring in 5 years. The expense is being recognized based on service terms of the agreement over a sixteen month period. The accounting expense recognized during 2011 is \$109,820. For the year ending December 31, 2012 and 2011, the Company recognized \$36,605 and \$109,820 of expense. The warrants are still outstanding as of December 31, 2012.

In May 2011, the board of directors approved a grant to a new outside director of an option to purchase up to 200,000 shares of common stock at a purchase price of \$1.12 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$193,686, fair value. The option expires in 5 years and vests 50,000 immediately and the remaining in annual equal installments of 50,000 over the next three years. The option is expensed over the vesting terms. The expense recognized during 2011 is \$79,702. For the year ending December 31, 2012 and 2011, the Company recognized \$48,510 and \$79,702 of expense. As of December 31, 2012, options to purchase 200,000 shares of common stock are still outstanding.

In May 2011, the Company has signed an agreement with an institutional investor to sell up to \$20 million of common stock. Under the agreement subject to certain conditions and at the Company's sole discretion, the institutional investor has committed to invest up to \$20 million in the Company's common stock over a 30-month period. The

Company filed a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares that may be issued to the institutional investor. The institutional investor is obligated to make purchases as the Company directs in accordance with the agreement, which may be terminated by the Company at any time, without cost or penalty. Sales of shares will be made in specified amounts and at prices that are based upon the market prices of the Company's common stock immediately preceding the sales to the institutional investor. The Company has issued 150,830 shares of common stock to the institutional investor as an initial commitment fee valued at \$162,896, fair value and 301,659 shares of common stock are reserved for additional commitment fees to the institutional investor in accordance with the terms of the agreement. During June, 2011 through December, 2012, the institutional investor purchased 3,724,285 shares of common stock for proceeds of \$5,049,999. The Company issued 76,177 shares of common stock as additional commitment fee, valued at \$134,283, fair value, leaving 225,482 in reserve for additional commitment fees. For the year ending December 31, 2012, the institutional investor purchased 3,539,100 shares of common stock for proceeds of \$4,849,999 and the Company issued 73,160 shares of common stock as additional commitment fee, valued at \$130,813, fair value.

During June 2011, the Company issued 10,000 shares of common stock for investor relations expense valued at \$10,400, fair value. The Company recognized \$10,400 of investor relations expense for the year ending December 31, 2011.

F-29

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

### **Common Stock and Warrants (Continued)**

In August 2011, the board of directors approved a grant to a new employee of an option to purchase up to 150,000 shares of common stock at a purchase price of \$1.01 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$123,241, fair value. The option expires in 5 years and vests in equal quarterly installments of 12,500 over the next three years beginning November 1, 2011. The expense recognized during 2011 is \$17,204. For the year ending December 31, 2012 and 2011, the Company recognized \$41,156 and \$17,204 of expense. As of December 31, 2012, options to purchase 150,000 shares of common stock are still outstanding.

During September 2011, the Company issued 10,000 shares of common stock for investor relations expense valued at \$14,500, fair value. The Company recognized \$14,500 of investor relations expense for the year ending December 31, 2011.

During 2011, the Company issued 2,018 shares of common stock to a director serving as a member of the Company s Operations Committee valued at \$2,163, fair value. The Company recognized \$2,163 of expense for the year ending December 31, 2011.

During 2011, the Company issued 1,000,000 shares of common stock and warrants to purchase 1,000,000 shares of common stock expiring September 2013 for proceeds of \$1,000,000 in accordance to a private placement memorandum dated August 26, 2011. Pursuant to the terms of the offerings, up to 4 units were offered at the purchase price of \$250,000 per unit, with each unit comprised of 250,000 shares and a warrant to purchase 125,000 shares of common stock at \$1.00 per share and a warrant to purchase 125,000 shares of common stock at \$1.25 per share. The warrants to purchase 500,000 shares of common stock at \$1.25 per share are still outstanding as of December 31, 2012.

In November 2011, the board of directors approved a grant to a new employee of an option to purchase up to 150,000 shares of common stock at a purchase price of \$0.63 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$78,764, fair value. The option expires in 5 years and vests in equal quarterly installments of 12,500 over the next three years beginning February 1, 2012. The expense recognized during 2011 is \$4,384. For the year ending December 31, 2012 and 2011, the Company recognized \$26,304 and \$4,384 of expense. As of December 31, 2012, options to purchase 150,000 shares of common stock are still outstanding.

In December 2011, the board of directors approved a grant to the member of its board of directors serving as the Company's non-executive chair of the board of directors of an option to purchase up to 250,000 shares of common stock at a purchase price of \$1.01 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$205,197, fair value. The option expires in 5 years and vests 62,500 immediately and the remaining in annual equal installments of 62,500 over the next three years. The expense recognized during 2011 is \$53,124. For the year ending December 31, 2012 and 2011, the Company recognized \$51,392 and \$53,124 of expense. As of December 31, 2012, options to purchase 250,000 shares of common stock are still outstanding.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

In December 2011, the board of directors approved a grant to a senior advisor of a warrant to purchase up to 150,000 shares of common stock at a purchase price of \$1.30 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$158,415, fair value. The warrant expires in 5 years and vests 37,500 immediately and the remaining in annual equal monthly installments of 9,375 over the next year. The expense recognized during 2011 is \$1,288. For the year ending December 31, 2012 and 2011, the Company recognized \$157,127 and \$1,288 of expense. As of December 31, 2012, warrants to purchase 150,000 shares of common stock are still outstanding.

During February 2012, the Company issued 1,406 shares of common stock to a director serving as a member of the Company s Operations Committee valued at \$1,607, fair value. For the year ending December 31, 2012, the Company recognized \$1,607 of expense.

In March 2012, the board of directors approved a grant to an employee of an option to purchase up to 100,000 shares of common stock at a purchase price of \$1.69 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$168,909, fair value. The option expires in 10 years and vests 25,000 immediately and the remaining vest 25,000 in six months, nine months and twelve months from date of grant. The option is expensed over the vesting terms. For the year ending December 31, 2012, the Company recognized \$139,755 of expense. As of December 31, 2012, option to purchase 100,000 shares of common stock are still outstanding.

In March 2012, the board of directors approved a grant to an employee of an option to purchase up to 25,000 shares of common stock at a purchase price of \$1.69 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$42,227, fair value. The option expires in 10 years with 12,500 vesting immediately and 12,500 vesting in six months from date of grant. The option is expensed over the vesting terms. For the year ending December 31, 2012, the Company recognized \$42,227 of expense. As of December 31, 2012, option to purchase 25,000 shares of

common stock are still outstanding.

In March 2012, the Company issued a warrant to purchase up to 10,000 shares of common stock for legal services at an exercise price of \$1.69 per share. Using the Black-Scholes Option Pricing Formula, the warrants were valued at \$13,709, fair value. These warrants expire in 5 years and vest immediately and are being expensed over the service period. For the year ending December 31, 2012, the Company recognized \$13,709 of expense. As of December 31, 2012, warrant to purchase 10,000 shares of common stock are still outstanding.

In May, 2012, the board of directors appointed its current Non-Executive Chairman of the board of directors as its new Chief Executive Officer and Executive Chairman of the board of directors and approved a grant of an option to purchase up to 500,000 shares of common stock at a purchase price of \$1.30 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$613,805, fair value. The option expires in 10 years and vests quarterly over one year in equal installments of 125,000 shares per quarter commencing on date of grant. The option is expensed over the vesting terms. For the year ending December 31, 2012, the Company recognized \$462,455 of expense. As of December 31, 2012, option to purchase 500,000 shares of common stock are still outstanding.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

### NOTE 7 STOCKHOLDERS EQUITY (CONTINUED)

#### **Common Stock and Warrants (Continued)**

During May 2012, the Company issued warrants to purchase 100,000 shares of common stock at a purchase price of \$1.20 per share for accounting services rendered commencing May 1, 2012. The warrant was valued at \$97,386 using the Black-Scholes Option Pricing Formula, vesting in thirteen monthly installments with 3,846 vesting at the beginning of each of the succeeding twelve months commencing June 1, 2012 and 3,848 the thirteenth month expiring in 5 years. The expense is being recognized based on service terms of the agreement over a fourteen-month period. For the year ending December 31, 2012, the Company recognized \$55,648 of expense. As of December 31, 2012, warrants to purchase 100,000 shares of common stock are still outstanding.

In June 2012, the board of directors appointed a new member of the board of directors and approved a grant of an option to purchase up to 200,000 shares of common stock at a purchase price of \$0.90 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$145,150, fair value. The option expires in 5 years and vests 50,000 immediately and the remaining in annual equal installments of 50,000 over the next three years. The option is expensed over the vesting terms. For the year ending December 31, 2012, the Company recognized \$56,568 of expense. As of December 31, 2012, option to purchase 200,000 shares of common stock are still outstanding.

In August 2012, the board of directors approved a grant to a new employee of an option to purchase up to 100,000 shares of common stock at a purchase price of \$0.925 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$74,486, fair value. The option expires in 5 years with 12,500 vesting every three months from date of grant. The option is expensed over the vesting terms. For the year ending December 31, 2012, the Company recognized \$15,611 of expense. As of December 31, 2012, option to purchase 100,000 shares of common stock are still outstanding.

In August 2012, the board of directors approved a grant to a new employee of an option to purchase up to 50,000 shares of common stock at a purchase price of \$0.93 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at \$37,486, fair value. The option expires in 5 years with 6,250 vesting every three months from date of grant. The option is expensed over the vesting terms. For the year ending December 31, 2012, the Company recognized \$7,137 of expense. As of December 31, 2012, option to purchase 50,000 shares of common stock are still outstanding.

Effective August 24, 2012, the number of shares of the Company s common stock available for issuance under the 2007 Employee Stock plan was increased from 6,500,000 to 8,000,000 shares.

In December 2012, the board of directors approved a grant to a senior advisor of a warrant to purchase up to 125,000 shares of common stock at a purchase price of \$0.93 per share. Using the Black-Scholes Option Pricing Formula, the warrant was valued at \$97,692, fair value. The warrant expires in 5 years with 31,256 vesting immediately and 7,812 vesting every month from date of grant. The warrant is expensed over the vesting terms. For the year ending December 31, 2012, the Company recognized \$28,237 of expense. As of December 31, 2012, warrant to purchase 125,000 shares of common stock is still outstanding.

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

#### NOTE 8 STOCK BASED COMPENSATION

The Company uses the Black-Scholes option pricing model to calculate the grant-date fair value of an award, with the following assumptions for 2012 and 2011: no dividend yield in both years, expected volatility, based on the Company s historical volatility, between 77% and 217% in 2012 and between 115% and 125% in 2011, risk-free interest rate between 0.13% and 2.26% in 2012 and between 0.82% and 2.15% in 2011 and expected option life of two to ten years in 2012 and three to five years in 2011.

As of December 31, 2012, there was \$829,247 of unrecognized compensation expense related to non-vested market-based share awards that is expected to be recognized through December 2014.

The following tables summarize all stock option and warrant activity of the Company since December 31, 2004:

F-33

(A Development Stage Company)

# NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

# NOTE 8 STOCK BASED COMPENSATION (CONTINUED)

	Non-Qualified Stock Opt Number of Shares	tions and Warrants Outst Exercise Price	anding and Exercisable Weighted Average Exercise Price
Outstanding, December 31, 2004	-	\$ -	\$
			\$
Granted	680,000	\$0.25 - \$2.10	0.99
Exercised	(300,000)	\$ 0.25	0.25
			\$
Outstanding, December 31, 2005	380,000	\$1.40 - \$2.10	0.68
			\$
Granted	1,425,000	\$0.25 - \$1.00	0.70
Cancelled	(260,000)	\$1.40 - \$2.10	(0.48)
Expired	(70,000)	\$1.40 - \$2.00	(0.12)
Outstanding, December 31,			\$
2006	1,475,000	\$0.25 - \$2.00	0.83
			\$
Granted Rescinded	5,768,971 (200,000)	\$0.25 - \$0.72 \$ 0.50	0.48

			\$	0.50
Forfeited	(125,019)	\$ 1.00	\$	1.00
Expired	(574,981)	\$ 1.00		1.00
Outstanding, December 31, 2007	6,343,971	\$0.25 - \$2.00	\$	0.48
Granted	3,495,001	\$0.001 - \$1.75	\$ \$	1.16
Expired	(115,000)	\$0.50 - \$2.00	\$	0.07
Forfeited	(750,000)	\$ 0.72	\$	0.72
Exercised	(807,770)	\$0.25 - \$0.50		0.53
Outstanding, December 31, 2008	8,166,202	\$0.001 - \$1.75	\$	0.79
Granted	939,000	\$0.25 - \$0.45	\$	0.30
Expired Forfeited	(1,304,451)	\$0.25 - \$1.00		0.59
Exercised	(1,488,384)	\$0.001 - \$1.00	\$	0.20
Outstanding, December 31, 2009	6,312,367	\$0.25 - \$1.75	\$	0.71
Granted	1,860,000	\$0.25 - \$1.51	\$	1.20
Expired Forfeited	(16,667)	\$ 1.00		1.00

			\$
Exercised	(1,279,700)	\$0.25 - \$1.00	0.42
Outstanding, December 31,			\$
2010	6,876,000	\$0.25 - \$1.75	1.01
			\$
Granted Expired	2,085,000	\$0.63 - \$1.30	1.09
Expired			\$
Forfeited Exercised	(162,500)	\$ 1.51	1.51
			\$
Outstanding, December 31, 2011	8,798,500	\$0.25 - \$1.75	1.02
			\$
Granted	1,210,000	\$0.90 - \$1.69	1.19
			\$
Expired Forfeited	(25,000)	\$ 1.25	1.25
			\$
Exercised	(1,210,000)	\$0.25 - \$1.25	0.37
Outstanding, December 31,			\$
2012	8,773,500	\$0.25 - \$1.75	1.13
			\$
Exercisable, December 31, 2012	7,714,850	\$0.25 - \$1.75	1.15
	F-34		

(A Development Stage Company)

#### NOTES TO FINANCIAL STATEMENTS

**DECEMBER 31, 2012** 

#### NOTE 8 STOCK BASED COMPENSATION (CONTINUED)

	Non-Qualified Stock Op	ptions and Warrants Outstandin	ng
	Number Outstanding	Weighted Average	Weighted Average
			Exercise Price of Options
Range of	Currently Exercisable	Remaining	and
Exercise	·	· ·	Warrants Currently
Prices	at December 31, 2012	Contractual Life	Exercisable
			\$
\$0.25 - \$1.75	7,714,850	2.71	1.15

#### NOTE 9 RELATED PARTY

At December 31, 2012 and 2011 the Company has accrued salaries to officers and two beneficial owners of \$48,650 and \$47,588.

# NOTE 10 SUBSEQUENT EVENTS

During January 2013, warrants for 600,000 shares issued in April 2008 at an exercise price of \$0.73 and an expiration date of April 2013 were amended to 400,000 shares at an exercise price of \$0.73 expiring October 2013 and 200,000 shares were rescinded.

During February, 2013 through March, 2013, the institutional investor under the Company s May 2011 agreement purchased 911,385 shares of common stock for proceeds of \$1,000,000. The Company issued 15,085 shares of

common stock as additional commitment fee, valued at \$19,550, fair value.

In March 2013, a new employee was granted an option to purchase up to 75,000 shares of common stock at an exercise price of \$1.16 per share. Using the Black-Scholes Option Pricing Formula, the options were valued at \$81,076, fair value. These options expire in 10 years and 9,375 shares vest quarterly commencing June 1, 2013. The option will be expensed over the vesting terms.

On March 12, 2013, the Company entered into an agreement with EM Photonics to co-develop an advanced telecom modulator.

During March 2013, the warrants issued under the July 2010 private placement memorandum as amended in September 2010, were extended three months with 156,250 warrants expiring on June 30, 2013 and 178,750 warrants expiring on September 8, 2013.

4,791,511 Shares

**Common Stock** 

**PROSPECTUS** 

April 18, 2013